Barclays Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $50

Benzinga · 1d ago
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $53 to $50.